Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Mergers Will Be More Defensive Going Forward, Abbott CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Investor wariness on the economic benefit of acquisitions will slow consolidation in the industry, White tells The Economist Pharmaceutical Roundtable. Sanofi-Aventis expects that any further consolidation will result from weakness.

You may also be interested in...

Roche Begins Search For Partner On Pipeline Products

Roche will need partners for its pipeline products, Head of Research Strategy Paul Nakagaki, PhD, said

Merck Defended By Sen. Hatch During Vioxx Hearing

Merck behaved "responsibly" in its handling of the COX-2 inhibitor Vioxx (rofecoxib), Sen. Orrin Hatch (R-Utah) said near the conclusion of a Nov. 18 Senate Finance Committee hearing on the withdrawn COX-2 inhibitor

Altace Patent Suit Cited By Icahn In Latest Missive Against Mylan/King Merger

Investor maintains that Cobalt Pharmaceuticals' patent challenge could mean a generic version of the ACE inhibitor will be launched in mid-2005. Mylan suggests that Icahn's opposition is motivated in part by desire to cash-in on short position in King.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts